--- title: "What 19 Analyst Ratings Have To Say About Inspire Medical Systems" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/275760186.md" description: "Inspire Medical Systems (NYSE:INSP) has received ratings from 19 analysts over the past three months, showing a mix of bullish and bearish sentiments. The average 12-month price target is $124.11, down from $127.35. Recent actions include several analysts lowering their ratings and price targets, while a few raised them. The company, focused on minimally invasive solutions for obstructive sleep apnea, reported a revenue growth rate of 10.49% and maintains strong profitability with a net margin of 4.42%. Its debt-to-equity ratio is low at 0.05, indicating conservative financial management." datetime: "2026-02-12T13:00:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275760186.md) - [en](https://longbridge.com/en/news/275760186.md) - [zh-HK](https://longbridge.com/zh-HK/news/275760186.md) --- > 支持的语言: [English](https://longbridge.com/en/news/275760186.md) | [繁體中文](https://longbridge.com/zh-HK/news/275760186.md) # What 19 Analyst Ratings Have To Say About Inspire Medical Systems In the preceding three months, 19 analysts have released ratings for Inspire Medical Systems (NYSE:INSP), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. **Bullish** **Somewhat Bullish** **Indifferent** **Somewhat Bearish** **Bearish** **Total Ratings** 3 9 7 0 0 **Last 30D** 0 2 3 0 0 **1M Ago** 0 1 1 0 0 **2M Ago** 1 2 2 0 0 **3M Ago** 2 4 1 0 0 Analysts have set 12-month price targets for Inspire Medical Systems, revealing an average target of $124.11, a high estimate of $180.00, and a low estimate of $70.00. A 2.54% drop is evident in the current average compared to the previous average price target of $127.35. ![price target chart](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770901236_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) ## Interpreting Analyst Ratings: A Closer Look A clear picture of Inspire Medical Systems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Adam Maeder Piper Sandler Lowers Overweight $85.00 $165.00 Richard Newitter Truist Securities Lowers Hold $70.00 $96.00 Anthony Petrone Mizuho Lowers Outperform $85.00 $130.00 Larry Biegelsen Wells Fargo Lowers Equal-Weight $70.00 $145.00 Mike Polark Baird Lowers Neutral $74.00 $130.00 Shagun Singh RBC Capital Lowers Sector Perform $90.00 $175.00 Larry Biegelsen Wells Fargo Lowers Overweight $145.00 $160.00 Richard Newitter Truist Securities Lowers Buy $120.00 $165.00 Danielle Antalffy UBS Raises Neutral $91.00 $89.00 Shagun Singh RBC Capital Raises Outperform $175.00 $125.00 Anthony Petrone Mizuho Raises Outperform $130.00 $110.00 Robbie Marcus JP Morgan Raises Neutral $118.00 $82.00 Adam Maeder Piper Sandler Raises Overweight $165.00 $135.00 Suraj Kalia Oppenheimer Announces Outperform $175.00 \- Mike Polark Baird Raises Outperform $180.00 $125.00 Kallum Titchmarsh Morgan Stanley Raises Equal-Weight $130.00 $105.00 Richard Newitter Truist Securities Raises Buy $165.00 $128.00 Mike Polark Wolfe Research Announces Outperform $180.00 \- Jonathan Block Stifel Raises Buy $110.00 $100.00 ### Key Insights: - **Action Taken:** Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inspire Medical Systems. This information offers a snapshot of how analysts perceive the current state of the company. - **Rating:** Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Inspire Medical Systems compared to the broader market. - **Price Targets:** Gaining insights, analysts provide estimates for the future value of Inspire Medical Systems's stock. This comparison reveals trends in analysts' expectations over time. Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Inspire Medical Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table. Stay up to date on Inspire Medical Systems analyst ratings. If you are interested in following small-cap stock news and performance you can start by tracking it here. ## Discovering Inspire Medical Systems: A Closer Look Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States. ### Unraveling the Financial Story of Inspire Medical Systems **Market Capitalization:** With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers. **Revenue Growth:** Inspire Medical Systems displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately **10.49%**. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers. **Net Margin:** Inspire Medical Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of **4.42%,** the company showcases strong profitability and effective cost management. **Return on Equity (ROE):** Inspire Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of **1.48%**, the company demonstrates effective use of equity capital and strong financial performance. **Return on Assets (ROA):** The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of **1.23%,** the company showcases effective utilization of assets. **Debt Management:** Inspire Medical Systems's debt-to-equity ratio is below the industry average at **0.05**, reflecting a lower dependency on debt financing and a more conservative financial approach. ## The Core of Analyst Ratings: What Every Investor Should Know Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are. Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update. Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error. This article was generated by Benzinga's automated content engine and reviewed by an editor. ### 相关股票 - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-CN/quote/IHI.US.md) - [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-CN/quote/XHE.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [Inspire Medical (INSP.US)](https://longbridge.com/zh-CN/quote/INSP.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) ## 相关资讯与研究 - [Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/zh-CN/news/279226861.md) - [BUZZ-MiniMed rises as FDA clears smartphone‑controlled insulin pump](https://longbridge.com/zh-CN/news/279614092.md) - [08:34 ETBiocare Medical and PreciPoint Announce Co-Exclusive Distribution Partnership to Expand Access to Digital Pathology for IHC and ISH](https://longbridge.com/zh-CN/news/279599959.md) - [Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity](https://longbridge.com/zh-CN/news/279446168.md) - [Stocks in Play: Ventripoint Diagnostics Ltd](https://longbridge.com/zh-CN/news/279451162.md)